{
    "title": "AstraZeneca pours cash into research and development as it hikes sales forecasts",
    "url": "https://www.dailymail.co.uk/money/markets/article-2824357/AstraZeneca-pours-cash-research-development-hikes-sales-forecasts.html",
    "date": "2014-11-06",
    "keywords": [
        "pfizer",
        "astrazeneca",
        "quarter",
        "company",
        "tax",
        "bid",
        "ftse",
        "normality",
        "takeover",
        "approach",
        "soriot",
        "companys",
        "independence",
        "pipeline",
        "cash",
        "research",
        "development",
        "operationsthe",
        "group",
        "launch",
        "nexium",
        "heartburn",
        "medicine",
        "quartersoriot",
        "regime",
        "rationale",
        "inversion",
        "cent",
        "digit",
        "exchange",
        "year",
        "brand",
        "cycle",
        "republic",
        "chain",
        "britain",
        "qataris",
        "investor",
        "move",
        "wharf",
        "estate",
        "price",
        "analyst",
        "patel",
        "investment",
        "management",
        "shift",
        "rd",
        "strategy",
        "growth",
        "speculation",
        "lockout",
        "drug",
        "patent",
        "cholesterol",
        "treatment",
        "crestor",
        "protection",
        "astra",
        "cancer"
    ],
    "category": [
        "money",
        "markets"
    ]
}